Pelthos Therapeutics Inc PTHS
News
Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
